Navigation Links
Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
Date:11/18/2011

ts in EYLEA.

The recommended dose for EYLEA is 2 mg administered by intravitreal injection every four weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg once every eight weeks (2 months).  Although EYLEA may be dosed as frequently as 2 mg every four weeks (monthly), additional efficacy was not demonstrated when EYLEA was dosed every four weeks compared to every eight weeks.

There is a potential risk of arterial thromboembolic events (ATEs) following use of intravitreal VEGF inhibitors, including EYLEA, defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).  The incidence of ATEs with EYLEA in clinical trials was low (1.8%).

Serious adverse reactions related to the injection procedure have occurred in less than 0.1% of intravitreal injections with EYLEA and include endophthalmitis, traumatic cataract, and increased intraocular pressure.

About the VIEW 1 and VIEW 2 Clinical StudiesThe safety and efficacy of EYLEA were assessed in two randomized, multi-center, double-masked, active-controlled studies in patients with wet AMD.  A total of 2412 patients were treated and evaluable for efficacy (1817 with EYLEA) in the two studies (VIEW 1 and VIEW 2). In each study, patients were randomly assigned in a 1:1:1:1 ratio to one of four dosing regimens: 1) EYLEA administered 2 mg every eight weeks following three initial monthly doses (EYLEA 2Q8); 2) EYLEA administered 2 mg every four weeks (EYLEA 2Q4); 3) EYLEA 0.5 mg administered every four weeks (EYLEA 0.5Q4); and 4) ranibizumab administered 0.5 mg every four weeks (ranibizumab 0.5Q4).  Patient ages ranged from 49 to 99 years with a mean of 76 years.

In both studies, the primary efficacy endpoint was the proportion of patients who maintained vision, defined as losing fewer than 15 letters of visual acuity at week 52 compared to baseline.  Data are available through week 52.
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
2. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
3. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
4. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
5. Regeneron Reports Second Quarter 2011 Financial and Operating Results
6. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
7. Trading in Regeneron Common Stock Halted
8. Regeneron Reports First Quarter 2011 Financial and Operating Results
9. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
10. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
11. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  A new analysis of Centers for Medicare and ... shows that 81 percent of seniors chose lower-cost preferred ... at certain pharmacies. The findings were released by ... now the foundation of Medicare Part D," said Pharmaceutical ...
(Date:1/23/2015)... WYNNEWOOD, Pa. , Jan. 23, 2015  MedScope ( ... has been nominated for a 2015 Connected World ... Personal Emergency Response System (mPERS), that can be used ... M2M technology partner.  In nominating MedScope, ...
(Date:1/23/2015)... and DUBLIN , Jan. 23, ... agreement with KRS Global Biotechnology, Inc. for the compounding, packaging ... compounded for shipment in the United States ... approved Outsourcing Facility capable of compounding naltrexone tablets in various ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4
... 12, 2011 The TandemHeart circulatory support system has ... Medicare Administrative Contractor (MAC) serving over 1.3 million beneficiaries ... of the United States. "We are extremely ... of the TandemHeart system," said  Kraig McEwen, President and ...
... Endologix, Inc. (NASDAQ: ELGX ), developer and ... details relating to the release of its second quarter 2011 ... 2011 after the close of the market. Endologix ... at 5:00 p.m. ET / 2:00 p.m. PT to discuss ...
Cached Medicine Technology:TandemHeart Approved for Expanded Reimbursement 2Endologix to Report Second Quarter 2011 Financial Results on July 21, 2011 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 The City of West ... 10 a.m., to commemorate the 42nd anniversary of the Supreme Court ... , “It’s been 42 years since the Roe vs. Wade decision ... still as present as ever,” said City of West Hollywood Councilmember ...
(Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, ... dresses. View website of AngelWeddingDress.com to find ... wedding dresses online for a bridal party. AngelWeddingDress offers ... for them. Its maternity wedding dresses are specially designed ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Thousand of ... Medical Care recalled its GranuFlo and NaturaLyte dialysis concentrates ... underway in U.S. District Court, District of Massachusetts, Bernstein ... 20th, the Court has remanded a case filed by ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television ... 32nd Annual Miami Breast Cancer Conference planned ... (PER®) , shares that “a fast-growing, virulent” cancer in ... had not followed up her clean mammogram with an ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... Solutions, and Blue Shield of California Look to Promote ... 17 The State of California,s efforts to move ... shot in the arm today as The California Public ... Medco Health Solutions, Inc., and Blue Shield of California ...
... PRA ) said today that A. M. Best ... The Group,s debt rating was also upgraded to "BBB." The ... http://www.newscom.com/cgi-bin/prnh/20081024/PROASSURANCELOGO ) , ... outstanding financial performance," said W. Stancil Starnes, the President and ...
... TMC207 and the discovery of new drugs to treat ... new landmark collaboration between the Global Alliance for TB ... and Tibotec Inc., (Tibotec), a global pharmaceutical company, has ... response to the urgent need to accelerate the discovery ...
... Which Currently Dominate the Market, Will Decline by $1 ... Report from Decision Resources , , WALTHAM, Mass., ... leading research and advisory firms for pharmaceutical and healthcare ... anti-amyloid monoclonal antibodies, most notably Elan/Wyeth,s bapineuzumab and Eli ...
... As job loss, bankruptcy, and divorce skyrocket with the global ... to cope. The burden of these concerns can be agonizing, ... "7 Proven Steps: How to Defeat Stress Without Going Through ... many different kinds of stress life can throw your way. ...
... June 17 Modern technology is affecting the lives ... The unique needs of elders and their sometimes faraway ... technologies. Consider the problem of an elderly person living ... to visit the doctor or to eat a meal. ...
Cached Medicine News:Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 2Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 3Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 4Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 5Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 6Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 7Health News:A. M. Best Upgrades ProAssurance Group to 'A' (Excellent) 2Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 2Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 3Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 4Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 5Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 6Health News:New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimer's Disease Market 2Health News:'7 Proven Steps: How to Defeat Stress Without Going Through the Embarrassment of Counseling': Proven Ways to Defeat Stress 2Health News:'7 Proven Steps: How to Defeat Stress Without Going Through the Embarrassment of Counseling': Proven Ways to Defeat Stress 3Health News:New Technology Assists Independent Seniors 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: